# Biotech Daily Digest — 2025-11-10

**38 items from 5 sources**

## Summary by Source

- Eli Lilly Press Releases: 1 item
- Endpoints News: 6 items
- Fierce Biotech: 14 items
- MHRA – News: 1 item
- arXiv q-bio: 16 items


## Eli Lilly Press Releases

- **[Queer Eye's Tan France helps unthread obesity bias as part of Zepbound's (tirzepatide) 'Changing the Thread Collection'](https://investor.lilly.com/news-releases/news-release-details/queer-eyes-tan-france-helps-unthread-obesity-bias-part-zepbounds)**  
  _Mon, 10 Nov 2025 09:12:00 -0500_  
  New innovative campaign weaves science and storytelling to help reframe obesity as a chronic disease INDIANAPOLIS , Nov. 10, 2025 /PRNewswire/ -- For Tan France, clothing has always been about more than appearance – it's about self-expression. As a stylist and advocate, he's spent years helping


## Endpoints News

- **[Ex-Lilly Diabetes leaders hunt for new obesity drugs at VC firm](https://endpoints.news/ex-lilly-diabetes-leaders-hunt-for-new-obesity-drugs-at-vc-firm/)**  
  _Mon, 10 Nov 2025 14:00:26 +0000_  
  ATLANTA — Two former executives of Eli Lilly's diabetes unit are searching for the newest and best approaches to obesity treatment.

 Enrique Conterno, former president of Lilly Diabetes, and his colleague Meg Powell teamed up earlier ...

- **[Roche reports two Phase 3 wins for its BTK inhibitor in multiple sclerosis](https://endpoints.news/roche-reports-two-phase-3-wins-for-its-btk-inhibitor-in-multiple-sclerosis/)**  
  _Mon, 10 Nov 2025 12:30:39 +0000_  
  Roche’s BTK inhibitor has cleared two registrational studies in different types of multiple sclerosis, a surprise turn for a drug class that’s seen several trial failures and safety setbacks.

 The Swiss drugmaker said Monday that ...

- **[#AHA25: Ionis claims curative potential for Tryngolza in severe triglyceride disease](https://endpoints.news/aha25-ionis-claims-curative-potential-for-tryngolza-in-severe-triglyceride-disease/)**  
  _Mon, 10 Nov 2025 12:03:22 +0000_  
  Ionis Pharmaceuticals CEO Brett Monia said that the company's antisense drug Tryngolza can function almost like a cure for a condition called severe hypertriglyceridemia (sHTG), in which patients have high levels of triglycerides.

 In twin ...

- **[AI biotech Iambic raises $100M from ARK, Regeneron](https://endpoints.news/ai-biotech-iambic-raises-100m-from-ark-regeneron/)**  
  _Mon, 10 Nov 2025 12:00:53 +0000_  
  Iambic Therapeutics has raised more than $100 million in a new funding round, CEO Tom Miller exclusively told Endpoints News, and the San Diego biotech plans on using the cash to advance multiple drugs in ...

- **[#AASLD25: Vir presents new hepatitis D data and ramps up bullish Phase 3 plans](https://endpoints.news/aasld25-vir-presents-new-hepatitis-d-data-and-ramps-up-bullish-phase-3-plans/)**  
  _Sun, 09 Nov 2025 23:15:42 +0000_  
  New data from Vir Biotechnology’s chronic hepatitis D treatment reinforce the combo regimen’s promise of keeping viral levels low, as the company's pivotal trials advance ahead of schedule.

 Vir said Sunday evening that a monthly ...

- **[#AHA25: Merck reports pivotal PCSK9 pill data in race to beat AstraZeneca to market](https://endpoints.news/aha25-merck-reports-pivotal-pcsk9-pill-data-in-race-to-beat-astrazeneca-to-market/)**  
  _Sun, 09 Nov 2025 22:00:40 +0000_  
  Merck’s lipid-lowering pill is on track to become the first oral PCSK9 inhibitor to reach the market, after positive data from two pivotal trials were presented at the American Heart Association's annual meeting over the ...


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/biotech/lilly-continues-ai-push-inking-100m-plus-research-pact-insilico" hreflang="en">Lilly continues AI push, inking $100M-plus research pact with Insilico</a>](https://www.fiercebiotech.com/biotech/lilly-continues-ai-push-inking-100m-plus-research-pact-insilico)**  
  _Nov 5, 2025 12:04pm_  
  Eli Lilly is inking a $100 million-plus biobucks deal with Insilico Medicine in hopes of using AI to discover new drugs.

- **[<a href="https://www.fiercebiotech.com/medtech/dna-testmaker-billiontoone-raises-314m-ipo-shares-take-quick-dip" hreflang="en">DNA test maker BillionToOne raises $314M in IPO, shares take a quick dip</a>](https://www.fiercebiotech.com/medtech/dna-testmaker-billiontoone-raises-314m-ipo-shares-take-quick-dip)**  
  _Nov 10, 2025 8:29am_  
  BillionToOne raised $314 million in the DNA test maker’s upsized initial public offering but saw share values slide after the first day of trading.

- **[<a href="https://www.fiercebiotech.com/medtech/guardant-blood-test-gives-early-warning-cancer-progression-chemo-patients-study-finds" hreflang="en">Guardant blood test gives early warning of cancer progression in chemo patients, study finds</a>](https://www.fiercebiotech.com/medtech/guardant-blood-test-gives-early-warning-cancer-progression-chemo-patients-study-finds)**  
  _Nov 10, 2025 8:07am_  
  Guardant Health is touting the results of a new study showing its Reveal blood test can detect if chemotherapy is failing months before evidence shows up on regular scans, allowing oncologists to switch treatment sooner.

- **[<a href="https://www.fiercebiotech.com/sponsored/medicus-pharma-advances-teverelix-prostate-cancer-and-urology" hreflang="en">Medicus Pharma Advances Newly Acquired Program Teverelix in Prostate Cancer and Urology</a>](https://www.fiercebiotech.com/sponsored/medicus-pharma-advances-teverelix-prostate-cancer-and-urology)**  
  _Nov 6, 2025 4:42pm_  
  Biotech firm prepares for pivotal trials as it positions Teverelix to address unmet needs in prostate cancer, urology and beyond.

- **[<a href="https://www.fiercebiotech.com/sponsored/syneos-health-executive-highlights-innovation-collaboration-clinical-trials" hreflang="en">Syneos Health executive highlights innovation, collaboration in clinical trials</a>](https://www.fiercebiotech.com/sponsored/syneos-health-executive-highlights-innovation-collaboration-clinical-trials)**  
  _Oct 29, 2025 2:01pm_  
  SVP David Burnham outlines how payer engagement, digital innovation and patient-centric design are reshaping clinical trials and accelerating development timelines.

- **[<a href="https://www.fiercebiotech.com/sponsored/phasev-ceo-now-time-embrace-ai-clinical-trial-success" hreflang="en">PhaseV CEO: Now is the Time to Embrace AI for Clinical Trial Success</a>](https://www.fiercebiotech.com/sponsored/phasev-ceo-now-time-embrace-ai-clinical-trial-success)**  
  _Nov 4, 2025 9:29am_  
  PhaseV’s transparent AI platform helps sponsors reduce trial failures and accelerate drug development through smarter design and real-world data integration.

- **[<a href="https://www.fiercebiotech.com/sponsored/foresight-diagnostics-executive-sees-mrd-testing-future-cancer-care" hreflang="en">Foresight Diagnostics executive sees MRD testing as future of cancer care</a>](https://www.fiercebiotech.com/sponsored/foresight-diagnostics-executive-sees-mrd-testing-future-cancer-care)**  
  _Nov 3, 2025 1:32pm_  
  Foresight Diagnostics shared insights into the evolving role of minimal residual disease (MRD) testing in precision oncology.

- **[<a href="https://www.fiercebiotech.com/sponsored/lumanitys-tom-murtagh-urges-early-clarity-drug-development-strategy" hreflang="en">Lumanity’s Tom Murtagh urges early clarity in drug development strategy</a>](https://www.fiercebiotech.com/sponsored/lumanitys-tom-murtagh-urges-early-clarity-drug-development-strategy)**  
  _Nov 3, 2025 10:32am_  
  Biotech leader outlines how early strategic alignment, cross-functional collaboration and AI-driven insights are reshaping commercialization success.

- **[<a href="https://www.fiercebiotech.com/sponsored/weaves-ai-platform-aims-revolutionize-regulatory-workflows-pharma" hreflang="en">Weave’s AI platform aims to revolutionize regulatory workflows in pharma</a>](https://www.fiercebiotech.com/sponsored/weaves-ai-platform-aims-revolutionize-regulatory-workflows-pharma)**  
  _Nov 3, 2025 12:46pm_  
  AI-powered platform streamlines regulatory processes, boosts collaboration and accelerates drug development timelines.

- **[<a href="https://www.fiercebiotech.com/biotech/lilly-bags-eye-catching-retinal-disease-gene-therapy-meiragtx-475m-deal" hreflang="en">Lilly bags eye-catching retinal disease gene therapy from MeiraGTx in $475M deal</a>](https://www.fiercebiotech.com/biotech/lilly-bags-eye-catching-retinal-disease-gene-therapy-meiragtx-475m-deal)**  
  _Nov 7, 2025 11:17am_  
  MeiraGTx is cashing in on a gene therapy that restored vision to 11 children who were born legally blind, licensing the program to Eli Lilly in a deal potentially worth more than $475 million.

- **[<a href="https://www.fiercebiotech.com/biotech/roche-reports-phase-3-multiple-sclerosis-wins-btk-inhibitor-succeeding-where-rivals-failed" hreflang="en">Roche reports phase 3 multiple sclerosis wins for BTK inhibitor, succeeding where rivals failed </a>](https://www.fiercebiotech.com/biotech/roche-reports-phase-3-multiple-sclerosis-wins-btk-inhibitor-succeeding-where-rivals-failed)**  
  _Nov 10, 2025 6:28am_  
  Roche has reported wins for its BTK inhibitor fenebrutinib in a pair of phase 3 multiple sclerosis trials. One victory was based on the finding that the candidate was non-inferior to Ocrevus, despite the company originally designing the study to show superiority to the incumbent MS treatment.

- **[<a href="https://www.fiercebiotech.com/biotech/astrazenecas-13b-bet-reduces-blood-pressure-14-mmhg-over-12-weeks-phase-3-win" hreflang="en">AstraZeneca's $1.3B bet reduces blood pressure by 14 mmHg over 12 weeks in phase 3 win</a>](https://www.fiercebiotech.com/biotech/astrazenecas-13b-bet-reduces-blood-pressure-14-mmhg-over-12-weeks-phase-3-win)**  
  _Nov 10, 2025 5:35am_  
  AstraZeneca's aldosterone synthase inhibitor baxdrostat reduced blood pressure by 14 mmHg over 12 weeks, the pharma has said in a first look at the data from a key phase 3 win.

- **[<a href="https://www.fiercebiotech.com/biotech/fda-puts-tenaya-heart-disease-gene-therapy-clinical-trial-hold" hreflang="en">FDA puts Tenaya heart disease gene therapy clinical trial on hold</a>](https://www.fiercebiotech.com/biotech/fda-puts-tenaya-heart-disease-gene-therapy-clinical-trial-hold)**  
  _Nov 10, 2025 5:18am_  
  The FDA has put a clinical hold on a Tenaya Therapeutics gene therapy study while the biotech works to standardize activities related to the immunosuppression regimen across trial sites.

- **[<a href="https://www.fiercebiotech.com/biotech/lilly-pens-12b-pact-sanegene-better-target-metabolic-rna-meds" hreflang="en">Eli Lilly pens $1.2B pact with Sanegene to better target metabolic RNA meds</a>](https://www.fiercebiotech.com/biotech/lilly-pens-12b-pact-sanegene-better-target-metabolic-rna-meds)**  
  _Nov 10, 2025 4:06am_  
  Eli Lilly has penned a research pact worth $1.2 billion in biobucks with SanegeneBio to help pinpoint cardiometabolic RNAi medicines at the correct tissues.


## MHRA – News

- **[Class 3 Medicines Recall: Zambon SpA, Emylif 50mg orodispersible film,  EL(25)A/47](https://www.gov.uk/drug-device-alerts/class-3-medicines-recall-zambon-spa-emylif-50mg-orodispersible-film-el-25-a-slash-47)**  
  _2025-11-10T10:02:35Z_  
  Zambon SpA is recalling an affected batch as a precautionary measure due to out of specification results for unknown impurities during ongoing stability testing.


## arXiv q-bio

- **[Shaping manifolds in equivariant recurrent neural networks](https://arxiv.org/abs/2511.04802)**  
  _Mon, 10 Nov 2025 00:00:00 -0500_  
  arXiv:2511.04802v1 Announce Type: new 
Abstract: Recordings of increasingly large neural populations have revealed that the firing of individual neurons is highly coordinated. When viewed in the space of all possible patterns, the collective activity forms non-linear structures called neural manifolds. Because such st…

- **[Duration-modulated neural population dynamics in humans during BMI controls](https://arxiv.org/abs/2511.04887)**  
  _Mon, 10 Nov 2025 00:00:00 -0500_  
  arXiv:2511.04887v1 Announce Type: new 
Abstract: The motor cortex (MC) is often described as an autonomous dynamical system during movement execution. In an autonomous dynamical system, flexible movement generation depends on reconfiguring the initial conditions, which then unwind along known dynamics. An open questio…

- **[Predicting Cognitive Assessment Scores in Older Adults with Cognitive Impairment Using Wearable Sensors](https://arxiv.org/abs/2511.04983)**  
  _Mon, 10 Nov 2025 00:00:00 -0500_  
  arXiv:2511.04983v1 Announce Type: new 
Abstract: Background and Objectives: This paper focuses on using AI to assess the cognitive function of older adults with mild cognitive impairment or mild dementia using physiological data provided by a wearable device. Cognitive screening tools are disruptive, time-consuming, a…

- **[Modelling variability of the immunity build-up and waning following RNA-based vaccination](https://arxiv.org/abs/2511.05130)**  
  _Mon, 10 Nov 2025 00:00:00 -0500_  
  arXiv:2511.05130v1 Announce Type: new 
Abstract: RNA-based vaccination has been broadly applied in the COVID pandemic. A characteristic of the immunization was fast waning immunity. However, the time scale of this process varied considerable for virus subtypes and among individuals. Understanding the origin of this va…

- **[PySlyde: A Lightweight, Open-Source Toolkit for Pathology Preprocessing](https://arxiv.org/abs/2511.05183)**  
  _Mon, 10 Nov 2025 00:00:00 -0500_  
  arXiv:2511.05183v1 Announce Type: new 
Abstract: The integration of artificial intelligence (AI) into pathology is advancing precision medicine by improving diagnosis, treatment planning, and patient outcomes. Digitised whole-slide images (WSIs) capture rich spatial and morphological information vital for understandin…

- **[Travelling waves modulated by subthreshold oscillations in networks of integrate-and-fire neurons](https://arxiv.org/abs/2511.05232)**  
  _Mon, 10 Nov 2025 00:00:00 -0500_  
  arXiv:2511.05232v1 Announce Type: new 
Abstract: Travelling waves of neural firing activity are observed in brain tissue as a part of various sensory, motor and cognitive processes. They represent an object of major interest in the study of excitable networks, with analysis conducted in both neural field models and sp…

- **[A Penny for Your Thoughts: Decoding Speech from Inexpensive Brain Signals](https://arxiv.org/abs/2511.04691)**  
  _Mon, 10 Nov 2025 00:00:00 -0500_  
  arXiv:2511.04691v1 Announce Type: cross 
Abstract: We explore whether neural networks can decode brain activity into speech by mapping EEG recordings to audio representations. Using EEG data recorded as subjects listened to natural speech, we train a model with a contrastive CLIP loss to align EEG-derived embeddings w…

- **[Stresses and fluid flow in lamina cribrosa through anisotropic poroelasticty](https://arxiv.org/abs/2511.04726)**  
  _Mon, 10 Nov 2025 00:00:00 -0500_  
  arXiv:2511.04726v1 Announce Type: cross 
Abstract: To explore the possible mechanical correlations between intraocular pressure (IOP) variations and glaucoma, this study presents a transversely isotropic poroelastic model of the Lamina Cribrosa (LC) based on Reissner Mindlin plate theory, ultimately highlighting the i…

- **[A Standardized Benchmark for Multilabel Antimicrobial Peptide Classification](https://arxiv.org/abs/2511.04814)**  
  _Mon, 10 Nov 2025 00:00:00 -0500_  
  arXiv:2511.04814v1 Announce Type: cross 
Abstract: Antimicrobial peptides have emerged as promising molecules to combat antimicrobial resistance. However, fragmented datasets, inconsistent annotations, and the lack of standardized benchmarks hinder computational approaches and slow down the discovery of new candidates…

- **[SPECTRA: Spectral Target-Aware Graph Augmentation for Imbalanced Molecular Property Regression](https://arxiv.org/abs/2511.04838)**  
  _Mon, 10 Nov 2025 00:00:00 -0500_  
  arXiv:2511.04838v1 Announce Type: cross 
Abstract: In molecular property prediction, the most valuable compounds (e.g., high potency) often occupy sparse regions of the target space. Standard Graph Neural Networks (GNNs) commonly optimize for the average error, underperforming on these uncommon but critical cases, wit…

- **[SigmaDock: Untwisting Molecular Docking With Fragment-Based SE(3) Diffusion](https://arxiv.org/abs/2511.04854)**  
  _Mon, 10 Nov 2025 00:00:00 -0500_  
  arXiv:2511.04854v1 Announce Type: cross 
Abstract: Determining the binding pose of a ligand to a protein, known as molecular docking, is a fundamental task in drug discovery. Generative approaches promise faster, improved, and more diverse pose sampling than physics-based methods, but are often hindered by chemically…

- **[LG-NuSegHop: A Local-to-Global Self-Supervised Pipeline For Nuclei Instance Segmentation](https://arxiv.org/abs/2511.04892)**  
  _Mon, 10 Nov 2025 00:00:00 -0500_  
  arXiv:2511.04892v1 Announce Type: cross 
Abstract: Nuclei segmentation is the cornerstone task in histology image reading, shedding light on the underlying molecular patterns and leading to disease or cancer diagnosis. Yet, it is a laborious task that requires expertise from trained physicians. The large nuclei variab…

- **[BiPETE: A Bi-Positional Embedding Transformer Encoder for Risk Assessment of Alcohol and Substance Use Disorder with Electronic Health Records](https://arxiv.org/abs/2511.04998)**  
  _Mon, 10 Nov 2025 00:00:00 -0500_  
  arXiv:2511.04998v1 Announce Type: cross 
Abstract: Transformer-based deep learning models have shown promise for disease risk prediction using electronic health records(EHRs), but modeling temporal dependencies remains a key challenge due to irregular visit intervals and lack of uniform structure. We propose a Bi-Posi…

- **[ActiTect: A Generalizable Machine Learning Pipeline for REM Sleep Behavior Disorder Screening through Standardized Actigraphy](https://arxiv.org/abs/2511.05221)**  
  _Mon, 10 Nov 2025 00:00:00 -0500_  
  arXiv:2511.05221v1 Announce Type: cross 
Abstract: Isolated rapid eye movement sleep behavior disorder (iRBD) is a major prodromal marker of $\alpha$-synucleinopathies, often preceding the clinical onset of Parkinson's disease, dementia with Lewy bodies, or multiple system atrophy. While wrist-worn actimeters hold sig…

- **[Generalizable, real-time neural decoding with hybrid state-space models](https://arxiv.org/abs/2506.05320)**  
  _Mon, 10 Nov 2025 00:00:00 -0500_  
  arXiv:2506.05320v2 Announce Type: replace 
Abstract: Real-time decoding of neural activity is central to neuroscience and neurotechnology applications, from closed-loop experiments to brain-computer interfaces, where models are subject to strict latency constraints. Traditional methods, including simple recurrent neur…

- **[Quantifying Uncertainty in Error Consistency: Towards Reliable Behavioral Comparison of Classifiers](https://arxiv.org/abs/2507.06645)**  
  _Mon, 10 Nov 2025 00:00:00 -0500_  
  arXiv:2507.06645v2 Announce Type: replace 
Abstract: Benchmarking models is a key factor for the rapid progress in machine learning (ML) research. Thus, further progress depends on improving benchmarking metrics. A standard metric to measure the behavioral alignment between ML models and human observers is error consi…
